Browse by Audience
Skip to content
Papers of the Week
Aprepitant in refractory pruritus of systemic lymphoproliferative disorders.
Authors
Abstract
Paraneoplastic pruritus represents a frequent symptom in the debut or progression of lymphoproliferative disorders. It affects approximately 30% of patients with Hodgkin lymphoma and 15% of patients with non-Hodgkin lymphoma(1). Aprepitant has shown promising results in the treatment of refractory pruritus of primary cutaneous T-cell lymphomas (CTCL)(2-4).